Singapore, Nov. 3 -- German firm Boehringer Ingelheim has licensed a pre-clinical programme from Japan's Kyowa Kirin to develop a potential first-in-class, small molecule for the treatment of autoimmune diseases.

Autoimmune diseases represent a substantial and growing global health challenge, affecting approximately one in ten people and imposing a significant burden on patients and healthcare systems. Despite progress in therapeutic innovation, there remains a high need for more effective and long-lasting treatment options. As a recognized leader in autoimmune disease research and development, Boehringer Ingelheim advances new approaches that target the root causes of autoimmune conditions, with the goal of delivering highly targeted ne...